Key Points
- Director Yezan Munther Haddadin bought 29,000 shares of Oncobiologics at $0.83 per share, spending about $24,070 and boosting his ownership by 78% to 66,167 shares.
- OTLK stock slipped 0.5% and was trading around $0.81, with the company carrying a market cap of about $113.4 million and a 52-week range of $0.16 to $3.39.
- The company recently posted a wider-than-expected quarterly loss, reporting EPS of -$0.16 versus estimates of -$0.12 and revenue of just $0.13 million versus $4.39 million expected; analysts currently rate the stock Hold on average.
Oncobiologics, Inc. (NASDAQ:OTLK - Get Free Report) Director Yezan Munther Haddadin acquired 29,000 shares of the business's stock in a transaction on Tuesday, June 2nd. The shares were purchased at an average price of $0.83 per share, for a total transaction of $24,070.00. Following the transaction, the director directly owned 66,167 shares of the company's stock, valued at approximately $54,918.61. The trade was a 78.03% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.
Oncobiologics Stock Down 0.5%
OTLK stock opened at $0.81 on Thursday. Oncobiologics, Inc. has a twelve month low of $0.16 and a twelve month high of $3.39. The stock has a market capitalization of $113.41 million, a price-to-earnings ratio of -0.69 and a beta of 0.96. The firm's fifty day simple moving average is $0.31 and its two-hundred day simple moving average is $0.76.
Oncobiologics (NASDAQ:OTLK - Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.04). The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $4.39 million. As a group, equities research analysts expect that Oncobiologics, Inc. will post -0.51 EPS for the current year.
Institutional Investors Weigh In On Oncobiologics
A number of institutional investors and hedge funds have recently bought and sold shares of OTLK. Russell Investments Group Ltd. raised its position in Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company's stock valued at $39,000 after purchasing an additional 21,941 shares in the last quarter. AQR Capital Management LLC raised its position in Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company's stock valued at $103,000 after purchasing an additional 25,351 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company's stock worth $126,000 after acquiring an additional 44,063 shares during the period. 11.20% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
OTLK has been the topic of a number of analyst reports. Weiss Ratings reiterated a "sell (e+)" rating on shares of Oncobiologics in a research report on Friday, March 27th. Ascendiant Capital Markets lowered their target price on shares of Oncobiologics from $10.00 to $6.00 and set a "buy" rating for the company in a research note on Wednesday, March 11th. HC Wainwright reissued a "neutral" rating on shares of Oncobiologics in a research note on Wednesday, February 18th. Chardan Capital reissued a "neutral" rating on shares of Oncobiologics in a research note on Wednesday, February 18th. Finally, BTIG Research reissued a "neutral" rating on shares of Oncobiologics in a research note on Monday, May 18th. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Oncobiologics presently has a consensus rating of "Hold" and a consensus price target of $4.50.
View Our Latest Report on Oncobiologics
Oncobiologics Company Profile
(
Get Free Report)
Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics' research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.
Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
